Heterozygous in-frame mutations (p.E2207del and p.R2308_M2309dup) in the a-II subunit of spectrin (SPTAN1) were recently identified in two patients with intellectual disability (ID), infantile spasms (IS), hypomyelination, and brain atrophy. These mutations affected the C-terminal domain of the protein, which contains the nucleation site of the a/b spectrin heterodimer. By screening SPTAN1 in 95 patients with idiopathic ID, we found a de novo in-frame mutation (p.Q2202del) in the same C-terminal domain in a patient with mild generalized epilepsy and pontocerebellar atrophy, but without IS, hypomyelination, or other brain structural defects, allowing us to define the core phenotype associated with these C-terminal SPTAN1 mutations. We also found a de novo missense variant (p.R566P) of unclear clinical significance in a patient with non-syndromic ID. These two mutations induced different patterns of aggregation between spectrin subunits in transfected neuronal cell lines, providing a paradigm for the classification of candidate variants. European Journal of Human Genetics (2012) 20, 796-800; doi:10.1038/ejhg.2011.271; published online 18 January 2012 Keywords: intellectual disability; epilepsy; SPTAN1; pontocerebellar atrophy
INTRODUCTION
The targeting and maintenance of groups of proteins at specific membrane domains of neurons, such as the synapse and the axon, are critical for the brain function and development. Not surprisingly, mutations in proteins that participate in the assembling of these domains, such as the spectrins, have been shown to cause neurological disorders. Spectrins consist of a-and b-subunits that form antiparallel heterodimers, which are assembled to form heterotetramers in a headto-head configuration. 1, 2 Heterozygous mutations in the b-III subunit (SPTBN2) were shown to cause spinocerebellar ataxia type-5. 3 Recently, de novo in-frame mutations in the a-II spectrin subunit (SPTAN1) were identified in patients with severe intellectual disability (ID), infantile spasms (IS) with hypsarrhythmia, hypomyelination, and atrophy of various regions of the brain, including the cerebellum and brainstem. 4 These mutations are located in a C-terminal domain that includes the nucleation site involved in a/b spectrin heterodimer formation. 5 Biochemical studies indicated that these mutations destabilized this interaction, leading to aggregation of a-II(mut)/b-II and a-II(mut)/b-III spectrin heterodimers in mouse cortical neurons and in lymphoblastoid cells from the patients. 4 Recent studies suggest that de novo point mutations in the germ line, which in humans are estimated to occur at a rate of B1.1Â10 À8 per base, may explain a large fraction of ID cases. [6] [7] [8] In the course of a project aimed to identify such mutations in candidate synaptic genes, we sequenced SPTAN1 in patients with idiopathic ID. We identified de novo mutations in SPTAN1 in a patient with non-syndromic ID and in a patient with ID, epilepsy and pontocerebellar atrophy, further expanding the phenotypical spectrum associated with mutations in SPTAN1. Moreover, we found that these mutations induce different patterns of aggregations of spectrin subunits in cultured neuronal cells, providing a paradigm to validate candidate variants and to establish correlations between genotypes and phenotypes.
METHODS

Subjects and DNA sequencing
Ninety-five cases of idiopathic ID (46 males and 49 females), mostly of FrenchCanadian ethnicity, without growth abnormalities or specific dysmorphic features, as well as 190 French-Canadians controls were studied. A subset of the ID cases (25/95) also displayed epilepsy. Genomic DNA was extracted from blood samples (Qiagen/Gentra, Toronto, ON, Canada) and paternity/maternity was confirmed using six informative unlinked microsatellite markers (Supplementary Table S1 ). Polymerase chain reaction amplification of all SPTAN1-coding exons and their splice junctions (Supplementary Table S2 for primers), DNA sequencing, and mutation analyses are detailed in the Supplementary Information.
Expression vectors
SPTAN1 mutants (c.1697G4C/p.R566P, c.6605_6607del/p.Q2202del, c.6619_ 6621del/p.E2207del; positions based on Refseq NM_001130438.2) were generated by site-directed mutagenesis using KOD-Plus-Mutagenesis kit (Toyobo, Osaka, Japan), and verified by sequencing. A full-length human SPTAN1 cDNA (a-II spectrin) with a C-terminal Flag-tag was cloned into a CAG-promoter vector to express C'-Flag-tagged a-II spectrin.
Cell culture, transfection, and immunofluorescence
Mouse neuroblastoma 2A (N2A) cells and primary cultures of mouse cortical neurons were grown, transfected, and tested by immunofluorescence for the expression of wild type and mutant spectrin subunits, as previously described, 4, 9 and detailed in the Supplementary Information.
RESULTS
We identified three heterozygous variants in SPTAN1 in different patients, including two missense (c.1679A4G/p.E560G and c.1697G 4C/p.R566P) and one in-frame amino-acid deletion (c.6605_ 6607del/p.Q2202del). p.E560G was transmitted from a healthy mother and is predicted not to affect protein function by various algorithms (Supplementary Table S3 ). In contrast, p.R566P (patient-1) and p.Q2202del (patient-2) were absent from the blood DNA of the corresponding healthy parents, indicating that they were de novo, and were not detected in 190 French-Canadian controls, nor reported in dbSNP134. p.R566P affects a well-conserved residue that lies at the N-terminus of SPTAN1 and is predicted to damage protein function by SIFT 10 and polyphen. 11 The deleted p.Q2202 residue is part of a C-terminal domain required for a/b spectrin subunit heterodimer formation. 5 Interestingly, p.Q2202del is in close proximity to the recently reported SPTAN1 in-frame mutations, p.E2207del and p.R2308_M2309dup, identified in patients with ID, IS, and structural brain defects (Figure 1 ). 4 The phenotypes of the patients with p.R566P and p.E2207del were different (Supplementary Information). Patient-1 (p.R566P), a 9-yearold boy, shows mild non-syndromic ID without epilepsy. The brain CT-scan did not reveal any abnormality. He has a sister who also shows non-syndromic ID but who does not carry the mutation. Patient-2 (p.Q2202del), an 11-year-old boy, shows severe ID. He did not present with IS but developed mild generalized epilepsy. The brain MRI showed severe atrophy of the cerebellum and mild atrophy of the brainstem, without any hypomyelination or other structural defects ( Figure 2 ). Expression of a-II spectrin containing p.E2207del or p.R2308_M2309dup induced subunit aggregates in primary neuronal cultures. 4 We took advantage of this assay to compare the impact of p.R566P, p.Q2202del, and p.E2207del in mouse N2A cells and mouse cortical neurons (Figure 3) . Expression of wild-type a-II spectrin in N2A cells resulted in its localization at cell periphery, without the formation of aggregates (Figures 3a and b) . The p.Q2202del mutant showed a similar pattern of expression whereas the p.E2207del induced small aggregates in 6% of transfected cells. In contrast, the p.R566P mutant induced large aggregates in 86% of transfected N2A cells. These mutant a-II spectrin aggregates colocalized with endogenous b-II spectrin (Supplementary Figure S1) . No endogenous b-IIIspectrin subunits were detectable in N2A cells by immunofluorescence. In primary neuronal cultures, p.E2207del induced aggregates in most cells; these aggregates were composed of both b-II and b-III spectrin subunits (Figures 3b-d) . The p.Q2202del mutant showed a similar aggregation profile, but in a lower proportion of cells (15-20%). In contrast, p.R566P induced aggregates in a much smaller number of cells (o5%). Moreover, double immunostaining revealed that these aggregates were composed of the b-II but not of the b-III spectrin subunit. 4 recently showed that in-frame deletion (p.E2207del) or duplication (p.R2308_M2309dup) in the C-terminal region of SPTAN1 causes a specific syndrome characterized by severe ID, IS, hypomyelination, and brain atrophy. 4 We describe here a novel inframe deletion in the same domain (p.Q2202del). The phenotype of the patient with this mutation (patient-2) overlaps with that of the previously described patients with in-frame C-terminal SPTAN1 mutations, although being milder. For instance, all three patients showed severe ID, but patient-2 was less impaired than the others. Moreover, the previously described patients presented early in life with IS, and their course was characterized by intractable seizures. In contrast, patient-2 did not show IS and his seizures were well controlled with a single antiepileptic drug. Finally, MRI studies revealed pontocerebellar atrophy in all three patients with the inframe mutations but patient-2 did not show atrophy of other structures or hypomyelination, like the others.
DISCUSSION
Saitsu et al
All three in-frame mutations induced the aggregation of the a-II with the b-II and b-III spectrin subunits in primary neuronal cells, suggesting that they have a dominant-negative effect. Although the spectrin aggregation profile associated with p.Q2202del was similar to that of p.E2207del, it was observed at a lower frequency correlating with the less severe phenotype observed in patient-2. Heterozygous mutations in b-III spectrin (SPTBN2) were previously shown to cause spinocerebellar ataxia type-5. 3 It is tempting to speculate that cerebellar atrophy in patients with mutations in SPTAN1 is caused at least in part by the aggregation of b-III spectrin. This is consistent with the fact that b-III, unlike b-II spectrin, is abundantly expressed in the human cerebellum (Allen Brain Atlas; http://human.brain-map.org/). All together, these observations strengthen the causal relationship between in-frame mutations at the C-terminus of SPTAN1, severe ID, and pontocerebellar atrophy, while expanding the phenotypical spectrum associated with these mutations. We also identified a de novo missense (p.R566P) in SPTAN1 in a patient with mild non-syndromic ID without epilepsy or any gross brain abnormalities. Interestingly, the aggregation profiles induced by p.R566P and by the in-frame mutations are different. First, p.R566P induced aggregates in a great proportion of N2A cells but only in a negligible proportion of primary neuronal cells. The reverse pattern was found with the in-frame mutations. Second, p.R566P only aggregated with b-II spectrin whereas the in-frame mutations showed aggregations with both b-II and b-III spectrin subunits in cortical neurons. The phenotypic differences between the patient with the missense and the patients with the in-frame mutations may thus be explained by the preferential aggregation of p.R566P a-II with b-II spectrin. It is important to underline that the sister of patient-1 was also diagnosed with non-syndromic ID but lacked p.R566P in her blood DNA. Although it is possible that she is a phenocopy, it appears more likely that p.R566P is not responsible for her brother's condition. The identification of other patients with deleterious mutations in the N-terminal region of SPTAN1 would help to distinguish these possibilities.
In summary, our work indicates that in-frame mutations in the C-terminus of SPTAN1 cause a core set of manifestations that include severe ID, generalized epilepsy, and pontocerebellar atrophy. Although it is unclear whether p.R566P is pathogenic, we found that this mutation induces a distinct pattern of spectrin aggregation. Additional studies are needed to determine whether this pattern of aggregation is associated with a specific phenotype. Our study thus provides a paradigm to validate candidate variants in SPTAN1 and to establish correlations between genotypes and phenotypes.
